Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;29(1):183-189.
doi: 10.1016/j.sjbs.2021.08.073. Epub 2021 Aug 27.

The association between two genetic polymorphisms in ITGB3 and increase risk of venous thromboembolism in cancer patients in Eastern Province of Saudi Arabia

Affiliations

The association between two genetic polymorphisms in ITGB3 and increase risk of venous thromboembolism in cancer patients in Eastern Province of Saudi Arabia

Asma Y Alsulaim et al. Saudi J Biol Sci. 2022 Jan.

Abstract

Venous thromboembolism (VTE) is one of the major complications in most cancer patients leading to poor prognosis and short survival. Several common clinical risk factors coexist in cancer patients are used as risk predictive biomarkers to help in the management and prevention of VTE. These include cancer site and stage, chemotherapy regimen and elevated biological markers. However, Genetic polymorphisms in genes controlling coagulation and fibrinolysis are significantly associated with VTE if detected, then they might be more sensitive individual predictive biomarkers for VTE risk assessment. This study was conducted to evaluate the association between ITGB3 rs3809865 and rs5918 with VTE risk as well as monitor the effect of VTE on overall survival of these cancer patients. In this retrospective case-control study, 195 cancer patients' formalin-fixed paraffin embedded tissue (FFPE) samples were collected (controls n = 157, case n = 38) using the stored data through Jan 2010 to Sep 2018 from King Fahad Specialist Hospital in Dammam. Samples were genotyped using TaqMan genotyping assay, then logistic regression analysis and Chi-square were used to predict the association between risk factors and VTE. Survival Comparison was tested by the log-rank test. Genetic polymorphisms in ITGB3 (rs3809865 and rs5918) found not to be associated with VTE increasing risk in cancer patients (p>0.05). While the advanced stage was potentially increasing the risk of VTE events (OR 5.1 CI 2.01-12.9p = 0.001). Patients with VTE showed a poor overall survival reflected by the median survival rate of only three years compared to seven years for cancer patients without VTE. This study highlighted the potential influence of VTE on prognosis and survival of cancer patients and raised the importance of exploring risk predictive biomarkers in our population. This will improve the risk prediction biomarkers leading to implementing safe and effective thrombosis prophylaxis strategies.

Keywords: Cancer; Eastern Province; Genetic Polymorphisms; ITGB3 gene; Risk; Saudi Arabia; Venous Thromboembolism.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Representative of direct sequence electropherogram of the gene region, ITGB3. Arrow indicates the position of rs3809865. (A) Sequence with genotype AA of rs3809865. (B) Sequence with genotype TT of rs3809865. A clear peak in electropherogram indicates a homozygous result.
Fig. 2
Fig. 2
Kaplan Meier survival curve. Kaplan Meier survival comparison between cases and controls shows clear difference in survival probabilities. Log Rank survival analysis revealed a statistically significant difference between cases and control survival with a p-value < 0.001.

Similar articles

Cited by

References

    1. Abdol Razak N.B., Jones G., Bhandari M., Berndt M.C., Metharom P. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers. 2018;10(10):380. - PMC - PubMed
    1. Agnelli G., Verso M., Mandalà M., Gallus S., Cimminiello C., Apolone G., Di Minno G., Maiello E., Prandoni P., Santoro A., Crinò L. A prospective study on survival in cancer patients with and without venous thromboembolism. Internal and emergency medicine. 2014;9(5):559–567. - PubMed
    1. Aleem A., Diab A.R.A., Alsaleh K., Algahtani F., Alsaeed E., Iqbal Z., El-Sherkawy M.S. Frequency, clinical pattern and outcome of thrombosis in cancer patients in Saudi Arabia. Asian Pacific Journal of Cancer Prevention. 2012;13(4):1311–1315. - PubMed
    1. Angelini, D. and Khorana, A.A., 2017, July. Risk assessment scores for cancer-associated venous thromboembolic disease. In Seminars in thrombosis and hemostasis (Vol. 43, No. 05, pp. 469-478). Thieme Medical Publishers. - PubMed
    1. Bennett J.S., Catella-Lawson F., Rut A.R., Vilaire G., Qi W., Kapoor S.C., Murphy S., FitzGerald G.A. Effect of the PlA2 alloantigen on the function of β3-integrins in platelets. Blood, The Journal of the American Society of Hematology. 2001;97(10):3093–3099. - PubMed

LinkOut - more resources